<DOC>
	<DOCNO>NCT02007512</DOCNO>
	<brief_summary>The purpose study determine enzalutamide give combination exemestane safe effective patient advance breast cancer .</brief_summary>
	<brief_title>Efficacy Safety Study Enzalutamide Combination With Exemestane Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>This Phase 2 , Randomized , Double-Blind , Placebo-Controlled , Multicenter Study Efficacy Safety Enzalutamide Combination With Exemestane Patients With Advanced Breast Cancer That Is Estrogen Progesterone Receptor Positive HER2-Normal .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Willing able provide inform consent ; Postmenopausal ; Advanced histologically confirm breast cancer ER+ , PgR+ , , HER2 normal ; Up one prior hormone therapy one prior chemotherapy advance setting allow ; Availability representative , formalinfixed , paraffinembedded tumor specimen enable diagnosis breast cancer viable tumor cell tissue block unstained serial slide accompany bay associate pathology report ; Measurable disease . Patients nonmeasurable bone skin disease manifestation advance breast cancer also eligible ; Eastern Cooperative Oncology Group ( ECOG ) status 0 1 ; Any severe concurrent disease , infection , comorbid condition render patient inappropriate enrollment opinion investigator ; Any condition reason interfere patient 's ability participate trial , may cause undue risk , complicate interpretation safety data , opinion investigator ; Current previously treat brain metastasis leptomeningeal disease ; Prior therapy ( &gt; 28 day ) exemestane metastatic setting ( Patients receive exemestane adjuvant set disease recurrence 1 year treatment discontinuation eligible ) ; Requires treatment tuberculosis HIV infection ; Radiation therapy within 7 day randomization ; History another invasive cancer within 5 year randomization ; History seizure condition may predispose seizure ; Clinically significant cardiovascular disease ; Active gastrointestinal disorder ; Major surgery within 28 day prior randomization ; Treatment oral anticancer nonhormonal anticancer agent within 14 day randomization ; Treatment approve investigational agent block androgen synthesis target androgen receptor ; Treatments follow medication within 14 day randomization : Estrogens , Androgens , Systemic radionuclides ; Hypersensitivity reaction exemestane .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>MDV3100</keyword>
	<keyword>Estrogen receptor positive ( ER + )</keyword>
	<keyword>Progesterone receptor positive ( PgR + )</keyword>
	<keyword>HER-2 normal</keyword>
</DOC>